| 2023-6-25 |
|
|
|
|
|
Therapeutic effects of isoquercetin on ovariectomy-induced osteoporosis in mice |
| Mengjing Wu, Mengyu Qin, Xian Wang |
| Laboratory of Analytical Chemistry of the State Ethnic Affairs Commission, School of Chemistry and Materials Science, South-Central Minzu University, Wuhan, 430074, China |
|
|
|
|
Abstract Bone marrow mesenchymal stem cells (BMSCs) are non-hematopoietic multipotent stem cells capable of differentiating into mature cells. Isoquercetin, an extract from natural sources, has shown promise as a potential treatment for osteoporosis. To investigate the therapeutic effects of isoquercetin on osteoporosis, bone marrow mesenchymal stem cells (BMSCs) were cultured in vitro, and osteogenesis or adipogenesis was induced in the presence of isoquercetin for 14 days. We evaluated cell viability, osteogenic and adipogenic differentiation, as well as mRNA expression levels of Runx2, Alpl, and OCN in osteoblasts, and mRNA expression levels of Pparγ, Fabp4, and Cebpα in adipocytes. The results showed that isoquercetin dose-dependently increased cell viability and promoted osteogenic differentiation, as evidenced by Alizarin Red and alkaline phosphatase staining and mRNA expression levels of Runx2, Alpl, and OCN in osteoblasts (P<0.05). In contrast, isoquercetin inhibited adipogenic differentiation and decreased the mRNA expression levels of Pparγ, Fabp4, and Cebpα in adipocytes (P<0.05). In vivo, isoquercetin treatment increased bone quantity and density in an osteoporosis model mice group, as determined by μCT scanning and immunohistochemistry (P<0.05). These findings suggest that isoquercetin may have therapeutic potential for osteoporosis by promoting the proliferation and differentiation of BMSCs towards osteoblasts while inhibiting adipogenic differentiation.
|
| Keywords
Osteoporosis
Isoquercetin
Bone marrow mesenchymal stem cells
Osteogenic induction
Adipogenic induction
|
| Fund:This work was supported by the National Natural Science Foundation of China (Grant Nos. 22276221, 21675176), the Fundamental Research Funds for the Central Universities, and South-Central Minzu University (Grant No. CZP21002) for financial support. |
|
Corresponding Authors:
Xian Wang,E-mail:xwang27@mail.scuec.edu.cn
E-mail: xwang27@mail.scuec.edu.cn
|
|
Issue Date: 18 July 2023
|
|
|
1 El-Gazzar A, Hogler W. Mechanisms of bone fragility: from osteogenesis imperfecta to secondary osteoporosis. Int J Mol Sci. 2021;22(2):18.
2 Hendrickx G, Boudin E, Van Hul W. A look behind the scenes: the risk and pathogenesis of primary osteoporosis. Nat Rev Rheumatol. 2015;11(8):462-74.
3 Costa-Paiva L, Gomes DC, Morais SS, et al. Knowledge about osteoporosis in postmenopausal women undergoing antiresorptive treatment. Maturitas. 2011;69(1):81-5.
4 Bouxsein ML, Myers KS, Shultz KL, et al. Ovariectomy-induced bone loss varies among inbred strains of mice. J Bone Miner Res. 2005;20(7):1085-92.
5 Colnot C. Skeletal cell fate decisions within periosteum and bone marrow during bone regeneration. J Bone Miner Res. 2009;24(2):274-82.
6 Kaur S, Raggatt LJ, Batoon L, et al. Role of bone marrow macrophages in controlling homeostasis and repair in bone and bone marrow niches. Semin Cell Dev Biol. 2017;61:12-21.
7 Li XD, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24(4):578-88.
8 Heino TJ, Hentunen TA. Differentiation of osteoblasts and osteocytes from mesenchymal stem cells. Curr Stem Cell Res Ther. 2008;3(2):131-45.
9 Fideles SOM, Ortiz AC, Assis AF, et al. Effect of cell source and osteoblast differentiation on gene expression profiles of mesenchymal stem cells derived from bone marrow or adipose tissue. J Cell Biochem. 2019;120(7):11842-52.
10 Cremers S, Drake MT, Ebetino FH, et al. Pharmacology of bisphosphonates. Br J Clin Pharmacol. 2019;85(6):1052-62.
11 Papapoulos S E: Use of bisphosphonates in the management of postmenopausal osteoporosis, Bilezikian J P, Grbic J T, editor, Bisphosphonates and Osteonecrosis of the Jaw, Malden: Wiley-Blackwell, 2011: 15-32.
12 Cummings SR, Santora AC, Black DM, et al. History of alendronate. Bone. 2020;137:7.
13 D’amelio P, Grimaldi A, Cristofaro MA, et al. Alendronate reduces osteoclast precursors in osteoporosis. Osteoporosis Int. 2010;21(10):1741-50.
14 Gupta S, Onkar A, Vashisht T. Zoledronic acid-induced unilateral anterior uveitis. Indian J Ophthalmol. 2020;68(9):2002-3.
15 Mbikay M, Chretien M. Isoquercetin as an Anti-Covid-19 medication: a potential to realize. Front Pharmacol. 2022;13:13.
16 Tumay S, Lale O, Nursel CB. An overview and management of osteoporosis. Eur J Rheumatol. 2017;4(1):46.
17 Guo DJ, Zhao MG, Xu W, et al. Dietary interventions for better management of osteoporosis: an overview. Crit Rev Food Sci Nutr. 2023;63(1):125-44.
18 Rajput R, Wairkar S, Gaud R. Nutraceuticals for better management of osteoporosis: an overview. J Funct Food. 2018;47:480-90.
19 Trivedi R, Kumar A, Gupta V, et al. Effects of Egb 761 on bone mineral density, bone microstructure, and osteoblast function: possible roles of quercetin and kaempferol. Mol Cell Endocrinol. 2009;302(1):86-91.
20 Tsuji M, Yamamoto H, Sato T, et al. Dietary quercetin inhibits bone loss without effect on the uterus in ovariectomized mice. J Bone Miner Metab. 2009;27(6):673-81.
21 Wang X, Schroder HC, Feng Q, et al. Isoquercitrin and polyphosphate co-enhance mineralization of human osteoblast-like SaOS-2 cells via separate activation of two RUNX2 cofactors AFT6 and Ets1. Biochem Pharmacol. 2014;89(3):413-21.
22 Fayed HA, Barakat BM, Elshaer SS, Abdel-Naim AB, Menze ET. Antiosteoporotic activities of isoquercitrin in ovariectomized rats: role of inhibiting hypoxia inducible factor-1 alpha. Eur J Pharmacol. 2019;865: 172785. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
